GlassScriptPhysician profile
Ellie Ebreo
NPI 1164466140
$3,420.38
in general payments reported to CMS, 2019-2025
25 companies · $1,556 in 2025
The $1,556 reported for 2025 was more than what 98% of Women'S Health Care, Ambulatory providers received nationally (typical 2025 total: $102).
See the full distribution for Women's Health Care, Ambulatory
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $175 · 2022: $163 · 2023: $516 · 2024: $1,011 · 2025: $1,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,983 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,983.33 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $325.51 | 2023-2024 | Accrufer |
| Abbott Laboratories | $226.10 | 2024-2025 | Freestyle Libre, Freestyle Libre 3 |
| Abbvie INC. | $210.07 | 2021-2023 | |
| Lilly USA, LLC | $208.84 | 2024-2025 | Zepbound, Mounjaro |
| Astellas Pharma US INC | $188.37 | 2024-2025 | Veozah |
| Mayne Pharma Commercial LLC | $184.01 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $170.04 | 2022-2024 | |
| Evofem Biosciences, INC. | $168.35 | 2022-2024 | Phexxi |
| Organon LLC | $167.77 | 2022-2025 | Nexplanon |
| Cvrx, INC. | $141.75 | 2025 | Barostim Neo System |
| Boston Scientific Corporation | $137.76 | 2025 | Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Astrazeneca Pharmaceuticals LP | $125.01 | 2024 | Farxiga |
| Corcept Therapeutics | $124.99 | 2025 | Korlym |
| Ascensia Diabetes Care US INC. | $123.00 | 2025 | |
| Phathom Pharmaceuticals, INC. | $119.94 | 2025 | Voquezna |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $118.85 | 2023-2025 | Slynd |
| Novo Nordisk INC | $115.42 | 2023 | Wegovy |
| Biogen, INC. | $115.23 | 2025 | Zurzuvae |
| Dexcom, INC. | $107.75 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Madrigal Pharmaceuticals | $98.25 | 2025 | Rezdiffra |
| Coopersurgical, INC. | $82.08 | 2025 | Paragard T 380a |
| Myovant Sciences INC. | $60.87 | 2022 | |
| Sumitomo Pharma America, INC. | $46.06 | 2023-2025 | Myfembree |
| Sage Therapeutics, LLC | $41.08 | 2024-2025 | Zurzuvae |
| Cumberland Pharmaceuticals, INC. | $13.28 | 2023 | Kristalose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellie Ebreo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.